crossword cybersecurity is a technology commercialisation company focusing exclusively on the cyber security sector. we work with research intensive european university partners to identify promising cyber security intellectual property ("ip") from research that our industry partners tell us meet emerging real-world challenges. our specialist cyber security software engineering team work with our university partners to develop the research concept into a fully fledged commercial product that we bring to market. our first product, rizikon (www.rizikon.io) is a cyber risk analysis and investment prioritisation tool that can help you understand where your biggest vulnerabilities are and how to invest in protecting against them. crossword cybersecurity plc was founded in 2014.
Company profile
Ticker
PBLA
Exchange
Website
CEO
Michael Cullen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cancer Prevention Pharmaceuticals, Inc. • Cancer Prevention Pharmaceuticals, LLC • Cancer Prevention Pharma (Ireland) Limited • Dublin, Ireland • Cancer Prevention Pharma Limited • Panbela Research, Inc. ...
PBLA stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Panbela Provides Business Update and Reports Q2 2023 Financial Results
10 Aug 23
8-K
Regulation FD Disclosure
19 Jul 23
8-K
Regulation FD Disclosure
10 Jul 23
8-K
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
21 Jun 23
424B4
Prospectus supplement with pricing info
20 Jun 23
EFFECT
Notice of effectiveness
16 Jun 23
CORRESP
Correspondence with SEC
9 Jun 23
CORRESP
Correspondence with SEC
6 Jun 23
S-1/A
IPO registration (amended)
2 Jun 23
Transcripts
PBLA
Earnings call transcript
2023 Q2
10 Aug 23
PBLA
Earnings call transcript
2023 Q1
4 May 23
PBLA
Earnings call transcript
2022 Q4
16 Mar 23
PBLA
Earnings call transcript
2022 Q3
10 Nov 22
PBLA
Earnings call transcript
2022 Q2
15 Aug 22
PBLA
Earnings call transcript
2022 Q1
14 May 22
PBLA
Earnings call transcript
2021 Q4
24 Mar 22
PBLA
Earnings call transcript
2021 Q3
12 Nov 21
PBLA
Earnings call transcript
2021 Q2
12 Aug 21
PBLA
Earnings call transcript
2021 Q1
13 May 21
Latest ownership filings
4
Jeffrey E. Jacob
14 Sep 23
4
Jennifer K. Simpson
29 Mar 23
4
Susan Horvath
29 Mar 23
4
Michael T. Cullen
29 Mar 23
4
Daniel Donovan
29 Mar 23
4
Arthur Fratamico
29 Mar 23
4
Jeffrey E. Jacob
29 Mar 23
4
JEFFREY S MATHIESEN
29 Mar 23
4
Donald Robert Schemel
29 Mar 23
SC 13G/A
Cullen Michael T.
14 Feb 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.21 mm | 7.21 mm | 7.21 mm | 7.21 mm | 7.21 mm | 7.21 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 1.99 mm | 1.73 mm | 1.91 mm | 1.84 mm |
| Cash used (since last report) | n/a | n/a | 5.43 mm | 4.71 mm | 5.21 mm | 5.01 mm |
| Cash remaining | n/a | n/a | 1.78 mm | 2.50 mm | 1.99 mm | 2.19 mm |
| Runway (months of cash) | n/a | n/a | 0.9 | 1.4 | 1.0 | 1.2 |
Institutional ownership, Q2 2023
33.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 9 |
| Opened positions | 2 |
| Closed positions | 14 |
| Increased positions | 0 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 945.12 mm |
| Total shares | 1.00 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lind Global Fund II | 590.00 k | $0.00 |
| Sabby Management | 235.82 k | $542.38 mm |
| Walleye Capital | 94.54 k | $217.43 mm |
| Hudson Bay Capital Management | 76.00 k | $174.80 mm |
| Tower Research Capital | 3.71 k | $8.54 mm |
| UBS UBS Group AG - Registered Shares | 823.00 | $1.89 mm |
| MS Morgan Stanley | 26.00 | $60.00 k |
| BAC Bank Of America | 2.00 | $5.00 k |
| Advisor | 2.00 | $4.00 k |
| Proequities | 0.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Sep 23 | Jeffrey E. Jacob | Common Stock | Gift | Dispose G | Yes | No | 0 | 275 | 0.00 | 0 |
| 27 Mar 23 | Schemel Donald Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
| 27 Mar 23 | Jeffrey E. Jacob | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
| 27 Mar 23 | Fratamico Arthur | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
| 27 Mar 23 | Michael T. Cullen | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 8,333 | 4.17 k | 8,333 |
News
Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
8 Sep 23
Panbela Announces Issuance Of New Patent In Chile For Claims Of A Novel Process For The Production Of Flynpovi
5 Sep 23
Stocks That Hit 52-Week Lows On Wednesday
23 Aug 23
HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
11 Aug 23
Panbela Therapeutics Q2 EPS $(7.95) Misses $(4.70) Estimate
10 Aug 23
Press releases
Panbela to Present at the LD Micro Investor Conference
19 Sep 23
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
5 Sep 23
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
28 Aug 23
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
14 Aug 23
Panbela Provides Business Update and Reports Q2 2023 Financial Results
10 Aug 23